…
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Femasys Inc is a clinical-stage medical device company focused on developing minimally invasive diagnostic and therapeutic solutions for women's reproductive health. Long-term growth may be supported by demographic trends increasing demand for gynecological and fertility care, successful regulatory clearances, and commercial adoption of its product pipeline. Investors may find exposure to niche women's-health innovation and potential upside if clinical milestones and market launches progress.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -18.63M | -18.81M | -14.24M | -11.39M | -7.53M |
| Net income | -18.63M | -18.82M | -14.25M | -11.39M | -7.54M |
| Selling general administrative | 6.65M | 6.33M | 6.86M | 5.43M | 4.26M |
| Selling and marketing expenses | 4.44M | 4.03M | 0.65M | 0.56M | 0.21M |
| Gross profit | 1.42M | 1.08M | 0.69M | 0.76M | 0.81M |
| Reconciled depreciation | 0.85M | 0.87M | 0.88M | 0.89M | 0.96M |
| Ebit | -16.74M | -17.20M | -14.08M | -11.60M | -8.34M |
| Ebitda | -15.89M | -16.33M | -13.17M | -10.81M | -6.92M |
| Depreciation and amortization | 0.85M | 0.87M | 0.91M | 0.79M | 1.41M |
| Operating income | -17.59M | -17.79M | -14.51M | -11.60M | -8.34M |
| Other operating expenses | 19.88M | 19.41M | 15.58M | 12.81M | 9.52M |
| Interest expense | 1.89M | 1.60M | 0.17M | 0.01M | 0.02M |
| Tax provision | 0.00M | 0.01M | 0.00M | 0.01M | 0.00M |
| Interest income | 0.10M | 0.58M | 0.35M | 0.23M | 0.00M |
| Net interest income | -1.79M | -1.02M | 0.34M | 0.21M | -0.02M |
| Income tax expense | 0.00M | 0.01M | 0.00M | 0.01M | 0.00M |
| Total revenue | 2.29M | 1.63M | 1.07M | 1.21M | 1.18M |
| Total operating expenses | 19.01M | 18.87M | 15.20M | 12.36M | 9.15M |
| Cost of revenue | 0.87M | 0.54M | 0.38M | 0.44M | 0.37M |
| Total other income expense net | -1.04M | -1.02M | 0.27M | 0.21M | 0.80M |
| Net income from continuing ops | -18.63M | -18.82M | -12.73M | -11.39M | -7.54M |
| Net income applicable to common shares | - | - | - | -11.39M | -7.54M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 20.72M | 12.45M | 27.76M | 16.90M | 28.58M |
| Intangible assets | 0.13M | 0.07M | - | 0.00M | 0.03M |
| Other current assets | 0.83M | 1.04M | 0.70M | 0.66M | 0.56M |
| Total liab | 14.85M | 10.14M | 9.40M | 1.65M | 2.24M |
| Total stockholder equity | 5.87M | 2.30M | 18.35M | 15.24M | 26.33M |
| Other current liab | 1.32M | 1.24M | 1.51M | 0.50M | 0.05M |
| Common stock | 0.06M | 0.02M | 0.02M | 0.01M | 0.01M |
| Capital stock | 0.06M | 0.02M | 0.02M | 0.01M | 0.01M |
| Retained earnings | -145.83M | -127.20M | -108.38M | -94.13M | -82.74M |
| Other liab | - | - | - | 0.10M | 0.15M |
| Other assets | - | 0.00M | - | 0.96M | 0.66M |
| Cash | 9.27M | 3.45M | 21.72M | 12.96M | 24.78M |
| Total current liabilities | 3.64M | 8.58M | 3.05M | 1.53M | 1.69M |
| Current deferred revenue | - | - | - | - | 0.60M |
| Net debt | -4.57M | 3.99M | -15.02M | -12.42M | -23.79M |
| Short term debt | 0.49M | 5.92M | 0.41M | 0.52M | 0.59M |
| Short long term debt | - | 5.41M | - | 0.19M | 0.18M |
| Short long term debt total | 4.70M | 7.44M | 6.70M | 0.54M | 0.99M |
| Other stockholder equity | 151.64M | 127.62M | 123.93M | 109.37M | 109.06M |
| Property plant equipment | - | - | - | 1.80M | 2.26M |
| Total current assets | 16.46M | 8.02M | 23.18M | 14.13M | 25.63M |
| Net tangible assets | - | - | - | 15.24M | 26.31M |
| Net receivables | 0.62M | 0.49M | 0.10M | 0.08M | 0.08M |
| Long term debt | 3.18M | - | 4.26M | - | - |
| Inventory | 5.74M | 3.05M | 0.67M | 0.44M | 0.21M |
| Accounts payable | 1.83M | 1.42M | 1.14M | 0.51M | 0.45M |
| Accumulated other comprehensive income | - | 1.86M | 2.79M | - | -28.58M |
| Non currrent assets other | 0.94M | 0.95M | 1.09M | 0.96M | 0.66M |
| Non current assets total | 4.27M | 4.42M | 4.58M | 2.76M | 2.95M |
| Capital lease obligations | 1.52M | 2.04M | 2.44M | 0.40M | 0.81M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.85M | -0.19M | -0.41M | -0.31M |
| Change to liabilities | - | - | - | 0.07M | -0.23M |
| Total cashflows from investing activities | -0.63M | -0.85M | -0.14M | -0.41M | -0.31M |
| Net borrowings | 4.15M | 0.00M | 6.22M | -0.53M | -0.46M |
| Total cash from financing activities | 25.14M | 2.03M | 20.18M | -0.68M | 29.70M |
| Change to operating activities | - | - | - | -0.30M | -0.47M |
| Net income | -18.63M | -18.82M | -14.25M | -11.39M | -7.54M |
| Change in cash | 5.81M | -18.26M | 8.75M | -11.82M | 21.46M |
| Begin period cash flow | 3.45M | 21.72M | 12.96M | 24.78M | 3.32M |
| End period cash flow | 9.27M | 3.45M | 21.72M | 12.96M | 24.78M |
| Total cash from operating activities | -18.69M | -19.44M | -11.28M | -10.73M | -7.93M |
| Issuance of capital stock | 19.52M | 2.03M | 3.98M | 0.08M | 31.74M |
| Depreciation | 0.80M | 0.87M | 0.91M | 0.89M | 0.96M |
| Other cashflows from investing activities | -0.11M | -0.09M | - | - | - |
| Change to inventory | -2.69M | -2.38M | -0.24M | -0.23M | -0.08M |
| Change to account receivables | -0.13M | 0.01M | -0.02M | 0.01M | 0.04M |
| Other cashflows from financing activities | -1.95M | 0.00M | 2.39M | -0.23M | -1.58M |
| Change to netincome | - | - | - | 0.23M | -0.62M |
| Capital expenditures | 0.53M | 0.76M | 0.14M | 0.41M | 0.31M |
| Change in working capital | -2.06M | -3.14M | 1.22M | -0.46M | -0.73M |
| Stock based compensation | 0.79M | 0.44M | 0.68M | 0.22M | 0.19M |
| Other non cash items | 0.40M | 1.20M | 0.16M | 0.01M | -0.82M |
| Free cash flow | -19.22M | -20.21M | -11.42M | -11.14M | -8.24M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FEMY Femasys Inc |
0.04 3.57% |
1.16 | - | - | 10.98 | 4.42 | 9.31 | 0.24 |
| ISRG Intuitive Surgical Inc |
-9.58 2.23% |
420.95 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
2.30 1.17% |
199.30 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
1.01 1.03% |
99.22 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
- -% |
216.08 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
| Name | Title | Year Born |
|---|---|---|
| Ms. Kathy Lee-Sepsick | Founder & CEO and Pres | 1967 |
| Mr. Daniel Scott Currie | SVP of Operations & Sec. | 1964 |
| Mr. Dov Elefant | Chief Financial Officer | 1967 |
| Ms. Mary An Merchant J.D., Ph.D. | VP of Counsel & Intellectual Property | NA |
| Mr. Steven P. Damon | VP of Bus. Devel. | 1956 |
| Mr. Todd A. Creech MBA | Chief Financial Advisor | 1968 |
| Dr. Jeffrey Marcus M.D., M.S. | Chief Medical Advisor | NA |
| Dr. Edward G. Evantash M.D. | Chief Medical Officer | 1963 |
| Ms. Christine Thomas | Sr. VP of Regulatory & Clinical Affairs | NA |
| Ms. Kathy Lee-Sepsick M.B.A. | Founder, President, CEO & Director | 1969 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.